| SHINO-TEST CORPORATION Patent applications |
| Patent application number | Title | Published |
|---|
| 20120129808 | BLOOD COAGULATION REACTION INHIBITOR - The present invention is a blood coagulation reaction inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The present invention is also a thrombin generation inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The blood coagulation reaction inhibitor and the thrombin generation inhibitor of the present invention are useful as an antithrombotic agent, a clinical laboratory test reagent for the blood coagulation-fibrinolysis system, and the like. | 05-24-2012 |
| 20110229487 | THERAPEUTIC AGENT COMPRISING ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO HUMAN HMGB-1 AS ACTIVE INGREDIENT - Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect. | 09-22-2011 |
| 20100216977 | THERAPEUTIC AGENT FOR INTERSTITIAL PULMONARY DISEASE COMPRISING ANTI-HMGB-1 ANTIBODY - An objective of the present invention is to provide effective methods for treating interstitial pulmonary diseases including interstitial pneumonia such as IPF. The present invention suggests that antibodies against HMGB-1 are effective for treating pulmonary fibrosis. Thus, the present invention provides preparations which comprise an anti-HMGB-1 antibody for treating interstitial pulmonary diseases. | 08-26-2010 |
| 20100173277 | Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody - An objective of the present invention is to provide effective methods for suppressing rejection in organ transplantation, in particular, pancreatic islet transplantation which is useful in treating diabetes. The present invention demonstrated that antibodies against HMGB-1 suppressed the rejection in pancreatic islet transplantation and promoted the survival of grafted pancreatic islets. Thus, the present invention provides agents that comprise an anti-HMGB-1 antibody for suppressing rejection in organ transplantation. | 07-08-2010 |
| 20090297546 | AVIAN-DERIVED ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO HUMAN HMGB1, IMMUNOLOGICAL DETERMINATION METHOD FOR HUMAN HMGB1, AND IMMUNOLOGICAL DETERMINATION REAGENT FOR HUMAN HMGB1 - An object of the present invention is to provide an anti-human HMGB1 antibody having high capability of binding to human high mobility group box protein- | 12-03-2009 |
| 20090017545 | Method of Determining Metal by Colorimetry and Determination Reagent - The present invention is a method for calorimetrically determining a metal in a sample using a chelating coloring agent, characterized by coexistence of a masking agent for iron, copper or nickel. Also, the present invention is a reagent for calorimetrically determining a metal in a sample using a chelating coloring agent, characterized by inclusion of a masking agent for iron, copper and/or nickel. Further, the present invention is a masking agent for iron, copper and/or nickel and a method for reducing positive errors due to iron, copper or nickel contained in a sample. | 01-15-2009 |
